GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development...

November 15th, 2011; Hyderabad, India: GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development organization, announced today a new partnership with the PROOF Centre of Excellence, focusing on biomarker development for heart, lung and kidney failure.
The PROOF (Prevention of Organ Failure) Centre, a not-for-profit Centre of Excellence for Commercialization and Research funded by the Government of Canada, has licensed the popular GVK BIO Online Clinical Biomarker Database (GOBIOM) to help evaluate the commercialization potential of the PROOF Centre's biomarkers for heart, lung and kidney disease.
"Heart, lung and kidney diseases are a tremendous cost to society - in dollars and lives. Our mission at the PROOF Centre is to create new tools that will help alleviate this global burden," says Dr. Bruce McManus, Director of the PROOF Centre. "Integrating knowledge from GVK Biosciences' Biomarker Database will be a significant advantage in helping us accelerate the transfer of these new tests into the clinic-ensuring patients will benefit faster."
The GOBIOM database is a comprehensive collection of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 14,000 biomarkers comprising of Biochemical, Genomic, Imaging, Metabolite, Cellular and Physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. Over 100 different ethnicities are covered in the database. The unique data model links the Biomarker to the Drug, Therapeutic Area and Target and allows users to query the database in multiple ways. The database also contains significant amount of Toxicity and Adverse Events data.
Sreeni Devidas, Vice President, Sales & Marketing - Informatics, said "the GOBIOM database has received good response from the academia and industry. The license by the PROOF Centre of Excellence further validates the utility of the database. We look forward to working with the researchers at the PROOF Centre of Excellence and helping them in their scientific strategies."
About GVK Biosciences
GVK Biosciences (GVK BIO) is Asia's leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO's diverse portfolio of more than 150 customers includes some of the world's largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic institutions. Please visit us at www.gvkbio.com to know more.
About the Proof Centre of Excellence
The PROOF (Prevention of Organ Failure) Centre is a not-for-profit organization that develops and implements blood-based biomarker tests to better manage patients with heart, lung and kidney risks and failure, and to prevent disease progression. By embracing a cross-disciplinary team of people and bringing all relevant organizations from all sectors together, we will speed up the development of these tests, applying them sooner to improve and save lives. The PROOF Centre is hosted by the University of British Columbia, and sited at St. Paul's Hospital in Vancouver, Canada. The PROOF Centre is supported by the Government of Canada through the Networks of Centres of Excellence for Commercialization and Research (CECR) program. To learn more please visit www.proofcentre.ca.
For any further information, please contact:
Sreeni Devidas Vice President - Sales & Marketing, Informatics GVK Biosciences Private Limited Columbia, MD 21045 T 001-443-838-6260 E [email protected] W www.gvkbio.com
Leah Lockhart Communications Manager PROOF Centre of Excellence 604-806-9853 cell: 778-960-0279 [email protected]
Sharada Alvakonda Dy General Manager - Corporate Communications GVK Biosciences Private Limited T 0044-743-8307768 E [email protected]

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.